Nigeria Psilocybin Assisted Therapy Market Size & Outlook, 2025-2033
Nigeria Psilocybin Assisted Therapy Market Insights
- As per Reed Intelligence insights, the Nigeria Psilocybin Assisted Therapy Market stood at USD 12.21 Billion in 2024 and is anticipated to grow to USD 42.96 Billion by 2033.
- The Nigeria market is expected to advance at a CAGR of 14.93% from 2026 through 2033.
- In 2024, Depression accounted for the highest share of the By Application market size.
- During the forecast period, Substance Abuse is set to register the highest growth, making it the most lucrative By Application segment.
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- Nigeria accounted for 0.51% of the global Psilocybin Assisted Therapy Market size in 2024.
- By 2033, United States is expected to remain the top global market in terms of size.
- Within Middle East and Africa, United Arab Emirates is forecasted to dominate the regional Psilocybin Assisted Therapy Market size by 2033.
- United Arab Emirates will be the fastest-growing market in Middle East and Africa, projected to achieve USD 406.94 Billion by 2033.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2024 |
| Study Period | 2021-2033 |
| Historical Period | 2021-2023 |
| Forecast Period | 2025-2033 |
| Market Size In 2024 | USD 12.21 Billion |
| Market Size In 2033 | USD 42.96 Billion |
| Largest segment | Depression |
| Units | Revenue in USD Billion |
| CAGR | 14.93% (2025-2033) |
| Segmnetation Covered | |
| By Application |
|
| Formulation |
|
| Therapeutic Setting |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
Nigeria Psilocybin Assisted Therapy Market By Application 2025-2033 (USD Billion)
| By Application | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Depression | XX.x | XX.x | XX.x | 4.46 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Anxiety | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Post-Traumatic Stress Disorder | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Substance Abuse | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Obsessive-Compulsive Disorder | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Nigeria Psilocybin Assisted Therapy Market Formulation 2025-2033 (USD Billion)
| Formulation | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liquid | XX.x | XX.x | XX.x | 5.42 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Tablet | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Capsule | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Powder | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Injection | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Nigeria Psilocybin Assisted Therapy Market Therapeutic Setting 2025-2033 (USD Billion)
| Therapeutic Setting | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Inpatient | XX.x | XX.x | XX.x | 4.88 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Outpatient | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Residential Treatment | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Community-Based Programs | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
